Dan Greer

Gastro Pharmacist LTHT

[Alexander Ford @alex_ford12399]

Our latest paper using liraglutide in patients with bile acid diarrhoea, some of whom had coexistent IBS-D. Is now published in @FrontGastro_BMJ:

https://t.co/sxeutl4XXn

@Maiskh_ @DrCJBlack

[The BMJ @bmj_latest]

A new BMJ study "reminds us not to overinterpret low certainty evidence in our efforts to reduce medication overuse," says this linked commentary.

"Doing so can lead us to misguided conclusions and potential harm"
https://t.co/EUurx2dAOT

[Keith Siau @drkeithsiau]

PPIs are one the most commonly (and inappropriately) prescribed drug classes out there. Grateful to my colleagues for producing this state-of-the-art review paper on PPIs, covering indications, harms and a guide for deprescribing 🆕 💊⚠️

🔗: https://t.co/BrmdARqNbz

[Keith Siau @drkeithsiau]

Distinguishing iron deficiency anaemia (IDA) from anaemia of chronic disease (ACD) 💡

📸: https://t.co/eWg4GgRlqx

[Seb @ibdseb]

JAK inhibitor induced acne seems to be troublesome in some #IBD patients .
Sharing this multi centre study including @IbdHull #IBDNurse @jodieIBDhull

https://t.co/ASUV2wMj2A

⏺️ Most common with Upadacitinib
⏺️ More so in 30+ years
⏺️ Dose dependent for Tof & UPA
⏺️ 1/3rd had negative psychological impact
⏺️ 40% needed dose reduction/ treatment

[Ashkan Rezazadeh MD PhD @AshkanRA]

🚨The Risk of Mild, Moderate and Severe Infections in #IBD – Prospective multicentre cohort study (PRIQ)

📌Understudied topic
💎In 629 pts, we found mild & moderate infections are common & linked to key risk factors (steroids doubled the risk👀)

@JCC_IBD https://t.co/588htbPIcx

[The ATLANTIS IBS Trial @atlantisIBS]

Tried everything for your IBS? The ATLANTIS trial found low-dose amitriptyline could help when other treatments don't. A new, evidence-based option for persistent symptoms. Ask your GP or visit the trial's website: https://t.co/rW9CqTw31F

[Christian Selinger @ChristianSelin3]

Interested in learning complex IBD management? Join us for 6 months in this exciting IBD fellowship. Leeds has a fabulous IBD team and the city is exciting.

https://t.co/HQKMGQxr4O

[Dr Paris Tavakoli @TavakoliParis]

Withdrawal of antitumour necrosis factor in inflammatory bowel disease patients in remission: a randomised placebo-controlled clinical trial of GETECCU | Gut https://t.co/uTH2YBopFf

[Frontline Gastro @FrontGastro_BMJ]

💉 As use of subcutaneous infliximab in IBD gathers pace, what do we know about the immune response of patients treated with SC vs IV IFX?

@sarahhhancox, Francesco Morda, @DrCJBlack and @ChristianSelin3 show that the risk of antidrug antibody formation is similar in SC vs IV IFX, with implications on the need for concurrent immunomodulator therapy.

Read all about it #onlinefirst in FG: https://t.co/wGSFewE8kK

@sheiybani @VivekGoodoory @RexWHHui @DunnePdj @DrJMKennedy @OTavabie @dr_aditi_kumar @PhilSmithIsBack

[Maillot à Pois E.Leclerc @maillotapois]

⚪️🔴 RT & follow pour tenter de gagner un maillot à pois dédicacé par Jonas Abrahamsen avec @SANTINI_SMS

⚪️🔴 RT & follow for the chance to win a @AbraJonas polka dot jersey with @SANTINI_SMS

#TDF2024

[roypounder.apt @APandT]

Results from 7442 patients with IBD: Stopping 5-aminosalicylate treatment after starting anti-TNF therapy did not show increased risk of adverse events. A significant finding for treatment strategies.
Read open access at https://t.co/YX9pA0UDwo
#GItwitter

[Dan Greer @danpgreer]

@m_cpharm @TUS_Athlone_ stop horsing around and get some work done

[Dan Greer @danpgreer]

Interesting - US intervention achieved a RR in PPI use of about 30% but no effect on GI symptoms or PPI assoc harms (unable to report effects on c.diff) . Also resulted in unintended reduction in appropriate gastroprotective use
https://t.co/G6XHcv86iq

[Keith Siau @drkeithsiau]

AGA update on IBD and malignancy @AGA_CGH 🆕📌

1️⃣ Malignancy related to IBD
2️⃣ What to do with IBD therapy if malignancy develops

https://t.co/EEgLSdStd9

[Gastroenterology @AGA_Gastro]

This week's most viewed article:

AGA Clinical Practice Update on De-Prescribing of Proton Pump Inhibitors: https://t.co/nTa8INZZGj

By authors from @UofT_DoM, @dukemedicine, and @UM_IHPI

#GERD #PPI

[Dan Greer @danpgreer]

Standard of Care Versus Octreotide in Angiodysplasia-Related Bleeding (the OCEAN Study): A Multicenter Randomized Controlled Trial - Gastroenterology https://t.co/4J4XxxOb6y

[Joost PH Drenth @joostphdrenth]

🆕@gastrojournal
👍 Gastrointestinal angiodysplasias may result in transfusion-dependency 🩸🩸
💉Octreotide effective?
🇳🇱RCT ➡️ YES
✏️NNT=2
🔗https://t.co/mFAT82sCds

[Claire Easthall @CEasthall]

Calling all pharmacy educational supervisors! 👩🏻‍🏫🎤. We're back for Spring 24, offering NHSE funded places in West Yorks for our highly-rated @LeedsHealthcare Educational Supervisor study sessions. Spread the word & get in touch for more info, let's get those trainers trained 👍